MSF Hits Back At ViiV Over ‘Infuriating’ Cabotegravir Approach

Welcomes MPP Deal For Generics, But Calls For More Transparency From Originator

05 Apr 2023

In the wake of a licensing deal with the MPP that will see three generics firms produce versions of ViiV’s long-acting cabotegravir for lower-income countries, Médecins Sans Frontières has urged the originator to be more transparent about plans to distribute the HIV prevention medicine in high-burden territories.

MSF has criticized ViiV over cabotegravir • Source: Shutterstock

Humanitarian organization Médecins Sans Frontières has urged ViiV Healthcare to provide more transparency over plans to make the firm’s long-acting cabotegravir HIV prevention treatment available in high-burden territories, in the wake of a licensing deal struck by the originator and the Medicines Patent Pool that will see three generics firms produce versions for least developed, low-income, lower-middle-income and sub-Saharan African countries.

Three generics firms – Aurobindo, Cipla and Viatris’s Mylan – recently signed licensing agreements with the MPP that will allow...

UK Decision Opens Up Competition On Forxiga

05 Aug 2025

• By Dave Wallace

Generic dapagliflozin rivals to AstraZeneca’s Forxiga are now free to hit the UK market after the country’s Supreme Court lifted the final barrier preventing launch, allowing off-patent firms access to a market worth hundreds of millions of pounds annually.

Sandoz Rushes To Fill Gap After German Court Revokes Xarelto Patent

04 Aug 2025

• By Dean Rudge

Germany’s Federal Patent Court has invalidated Bayer’s key patent covering once-daily use of Xarelto (rivaroxaban), paving the way for Sandoz to launch a generic version. Bayer is considering an appeal.

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

01 Aug 2025

• By Anju Ghangurde

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

US Court Agrees To Throw Out Viatris Wegovy Infringement Case

28 Jul 2025

• By Dean Rudge

Viatris’ Mylan has won a key patent case against Novo Nordisk over generic Wegovy, with a US federal district judge ruling Mylan’s label did not encourage use that infringed Novo’s method-of-treatment patent.

Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals

12 Aug 2025

• By Dean Rudge

Viatris and Amphastar are expanding their complex generic portfolios with the planned launches of FDA-approved versions of Vifor Pharma/Daiichi Sankyo’s Venofer (iron sucrose). The FDA’s database also show Sandoz holds an approval for generic Venofer, though it has not disclosed launch plans.